Adjuncts for Single-Injection Nerve Blocks

Disclaimer: This article is intended solely for informational and educational purposes only. It does not constitute medical advice.

Single-injection peripheral nerve blocks provide effective perioperative analgesia but are limited by the duration of action of local anesthetics, which is short relative to the duration of significant postoperative pain for some surgeries. Though catheters may deliver targeted analgesia over longer durations, they carry other risks and are not suitable for all cases. These limitations have prompted the use of adjuvant medications intended to prolong analgesia, reduce local anesthetic requirements, or improve block quality. Commonly studied adjuncts for single-injection nerve blocks include dexamethasone, dexmedetomidine, clonidine, epinephrine, and opioids.

Dexamethasone is the most extensively studied adjunct for peripheral nerve blocks and has demonstrated clinically meaningful prolongation of analgesia. When administered perineurally, dexamethasone can substantially prolong sensory and analgesic blockade compared with local anesthetic alone, although the magnitude of benefit varies according to block type and local anesthetic. Intravenous dexamethasone also prolongs block duration and may provide additional antiemetic and opioid-sparing benefits. Meta-analyses suggest that perineural administration may provide a modest additional duration of analgesia compared with intravenous administration, but the clinical significance of this difference remains uncertain. Because perineural dexamethasone is not universally approved for this indication and concerns remain regarding formulation-specific neurotoxicity, many clinicians favor intravenous administration when appropriate. 

Alpha-2 adrenergic agonists, particularly dexmedetomidine and clonidine, have also been investigated as peripheral nerve block adjuncts. Dexmedetomidine may prolong sensory and motor blockade and improve postoperative analgesia when administered perineurally. However, systemic absorption can produce bradycardia, hypotension, and sedation. Clonidine has similar effects but generally provides less consistent prolongation of analgesia. These adverse effects and variability in efficacy have limited the adoption of these agents as adjuncts to single-injection nerve blocks compared with dexamethasone. 

Epinephrine may be added to local anesthetic solutions to reduce systemic absorption and prolong local anesthetic exposure at the injection site. It can also serve as a marker of inadvertent intravascular injection through its cardiovascular effects. However, the analgesic benefit of epinephrine is generally modest and varies by block location and local anesthetic. Clinicians should use caution in areas with limited collateral blood flow or in patients at increased risk from systemic adrenergic effects. 

Opioids have historically been investigated as peripheral nerve block adjuncts, but their role is limited. Although agents such as morphine and buprenorphine may prolong analgesia in some settings, the evidence is inconsistent and systemic adverse effects—including nausea, vomiting, pruritus, sedation, and respiratory depression—reduce their attractiveness. Other agents, including magnesium, ketamine, and nonsteroidal anti-inflammatory drugs, have also been studied, but evidence supporting routine use remains less robust. 

Selection of an adjunct should therefore be individualized according to the desired duration of analgesia, patient comorbidities, block location, and institutional practice. Dexamethasone currently has the most consistent evidence for extending the duration of single-injection peripheral nerve blocks, while dexmedetomidine and clonidine may be useful alternatives in selected patients. Importantly, increasing block duration is not always synonymous with improved patient outcomes. Prolonged motor blockade can delay mobilization, increase fall risk, and obscure evolving neurologic deficits. The goal should be to provide sufficient analgesia for the expected period of severe postoperative pain while preserving functional recovery. Mild to moderate postoperative pain may be sufficiently controlled through non-opioid oral medication. 

For anesthesiologists, adjuvants are best viewed as tools for optimizing_—rather than simply maximizing_—block duration. Patient selection, appropriate local anesthetic dosing, ultrasound-guided technique, and careful monitoring remain more important than the choice of any single adjunct. As newer long-acting local anesthetic formulations and continuous catheter techniques evolve, the role of nerve block adjuncts will continue to be refined. 

References 

1. Abdallah FW, Johnson J, Chan V, et al. Intravenous versus perineural dexamethasone as a local anesthetic adjuvant for peripheral nerve block: a systematic review and meta-analysis. Reg Anesth Pain Med. 2015;40(6):639-645. DOI: 10.1097/AAP.0000000000000571 

2. Albrecht E, Vorobeichik L, Jacot-Guillarmod A, Fournier N, Abdallah FW. Dexamethasone is superior to dexmedetomidine as a peripheral nerve block adjuvant: a systematic review and indirect meta-analysis. Anesth Analg. 2019;128(3):543-554. DOI: 10.1213/ANE.0000000000003860 

3. Vorobeichik L, Brull R, Bowry R, et al. Perineural dexamethasone is more effective than intravenous dexamethasone for prolonging analgesia after peripheral nerve blockade: a systematic review and meta-analysis. Reg Anesth Pain Med. 2017;42(3):319-327. DOI: 10.1111/aas.70010 

4. Pöpping DM, Elia N, Marret E, Wenk M, Tramèr MR. Clonidine as an adjuvant to local anesthetic for peripheral nerve and plexus blocks: a meta-analysis of randomized trials. Anesthesiology. 2009;111(2):406-415. DOI: 10.1097/ALN.0b013e3181aae897